Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr challenges key US patents for Oxytrol

This article was originally published in Scrip

Executive Summary

Barr Laboratorieshas initiated a challenge to patents listed by Watson Laboratoriesin connection with Oxytrol (oxybutynin transdermal system). The ANDA contains a paragraph IV certification stating that the patents are invalid, unenforceable, or will not be infringed. Barr believes it is the first to file an application with the agency with a paragraph IV challenge. On October 23rd, Watson filed suit in the US District Court for the District of Delaware, alleging infringement of eight patents and triggering the 30-month stay of approval. The patents listed in the Orange Book for the product expire between 2010 and 2015, and most are method-of-use patents. Oxytrol has annual US sales of about $39 million, Barr said.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts